secwatch / observer
8-K filed March 19, 2026, 7:59 PM ET ticker BFRI CIK 0001858685
earnings confidence high sentiment positive materiality 0.80

Biofrontera reports record Q4 revenue $17.1M, net income $5.6M; full-year 2025 revenue up 12% to $41.7M

Biofrontera Inc.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biofrontera Inc. reported the fiscal year ended December 31, 2025 results: revenue $41.7 million, net income $10.5 million.

Period
the fiscal year ended December 31, 2025
Revenue
$41.7 million
Net income
$10.5 million
Result
reported results
Exact text from the filing
GAAP to non-GAAP reconciliation of Adjusted EBITDA for the fourth quarters of 2025 and 2024. Full Year 2025 Financial Results Total revenues for full year 2025 increased 12% to $41.7 million compared with $37.3 million for the full year 2024. Gross profit margin for the full year 2025 was 73.7% compared to 50.1% for the prior year. Cost of goods sold related party
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biofrontera Inc. reported the fourth quarter ended December 31, 2025 results: revenue $17.1 million, net income $5.6 million.

Period
the fourth quarter ended December 31, 2025
Revenue
$17.1 million
Net income
$5.6 million
Result
reported results
Exact text from the filing
financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights ● Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024. ● Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in
View on SEC.gov

Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR
accession 0001493152-26-011545
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.